Cardiology
Page 1 • 8 itemsGlobal cardiology market insights for pharma BD, investors & analysts. Track pipeline, M&A, regulatory updates & competitive intelligence.
Cytokinetics to Report Aficamten Phase 3 Trial Results for Non-Obstructive Hypertrophic Cardiomyopathy May 5, 2026
Cytokinetics announces topline results from pivotal ACACIA-HCM Phase 3 trial of aficamten for non-obstructive hypertrophic cardiomyopathy on May 5, 2026.
Boston Scientific FARAPULSE and WATCHMAN Show Positive Safety Data at Heart Rhythm 2026
Boston Scientific presents positive clinical trial data for FARAPULSE Pulsed Field Ablation and WATCHMAN devices at Heart Rhythm 2026 conference.
Adagio Medical's vCLAS Ventricular Ablation System Shows 84% Success Rate in Pivotal Trial for Heart Arrhythmia Treatment
Adagio Medical's vCLAS system achieved 84% freedom from shock and 59% freedom from VT recurrence in FULCRUM-VT pivotal trial, meeting primary endpoints.
Pulse Biosciences nPulse Cardiac Catheter Shows High Durability in Heart Rhythm 2026 Trial Data
Pulse Biosciences presents positive multicenter trial results for nPulse cardiac catheter system, showing sustained durability for atrial fibrillation treatment.
Abbott TactiFlex Duo Ablation Catheter Shows Positive Results for Complex AFib Treatment at Heart Rhythm Society 2026
Abbott presents positive 6-month FlexPulse IDE study results for TactiFlex Duo Ablation Catheter treating complex atrial fibrillation at Heart Rhythm Society 2026.
Medtronic Affera Sphere-9 Catheter Receives FDA Breakthrough Device Designation for Ventricular Tachycardia Treatment
Medtronic's Sphere-9 catheter gains FDA breakthrough status for VT treatment while Sphere-360 shows consistent durability across patient anatomies in new clinical data.
Health Canada Approves Bracco's VUEWAY (Gadopiclenol) for Lower-Dose MRI Contrast Imaging
Health Canada approves Bracco's VUEWAY injection (gadopiclenol) for MRI contrast imaging, enabling lower gadolinium doses while maintaining diagnostic quality.
FDA Approves RAPIBLYK (Landiolol) for Pediatric Supraventricular Tachycardia - AOP Health US Expands Critical Care Treatment Options
FDA approves RAPIBLYK (landiolol) by AOP Health US for pediatric patients with supraventricular tachycardia, expanding critical care treatment options.